Dr. Charles Benjamin Hensley

He is a graduate of the University of Oklahoma B.S. (Zoology), California State University, Long Beach (Marine Biologists) and received his Ph.D. from the University of Southern California in physiology and neuroscience. 

************

"The Rise and Fall of Dr. Charles Benjamin Hensley: A Tale of Innovation and Ambition" is a biographical account of the life of Dr. Charles Benjamin Hensley successful entrepreneur who rose to fame from humble beginnings in Oklahoma. 

In the depths of a bustling laboratory (Long Beach California), where the scent of formaldehyde filled the air, a young and ambitious shark biologist named Hensley embarked on a quest to unravel the mysteries of the ocean's apex predators. Under the guidance of renowned expert Dr. Donald Nelson, Hensley dove headfirst into the world of research, driven by an insatiable curiosity and a thirst for knowledge.  

The 1975 movie Jaws was based on the 1974 bestselling novel by Peter Benchley, but to make the film, Steven Spielberg had to condense, adapt, and flesh out the visuals. For research, he went to the Shark Lab at Cal State, founded by marine biologist Dr. Donald “Reef” Nelson. Spielberg was impressed by Nelson's knowledge -and his office, which served as the inspiration for that of the movie's marine biologist character Matt Hooper, played by Richard Dreyfuss.
 

Austin K. Mircheff was his academic advisor or supervisor during his Ph.D. research. Hensley completed his post-doctoral fellowship at the University of Southern California School of Medicine (Alicia McDonough, Ph.D,)..

As he delved deeper into his work, Hensley's passion for discovery only grew stronger. He became an innovator, a visionary, and a scientific trailblazer, always pushing the boundaries of what was thought possible. His groundbreaking research led Dr. Charles Benjamin Hensley and Rob Davidson, Ph.D. to develop ZICAM, a revolutionary cold remedy that would soon become an iconic American brand.

Dr Hensley is an international known innovator, visionary, entrepreneur, scientific with a global footprint. He has been featured in USA Today, Time Magazine and has appeared on CNBC Squawk Box Asia. Dr Hensley, discover and development ZICAM cold and remedy (considering by many “the cure for the common Cold”), founded ZICAM LLC and went on to market this iconic American brand. Dr Hensley has written two novels, 

COLD WARS and FLU WARS. Cold Wars is the story of his discovery and marketing of ZICAM. FLU WARS is Dr Hensley account of his scientific and political experience with emerging viral disease such SARS and Avian influenza. 

Pharmaceuticals

In 1997, Hensley invented and developed Zicam cold remedy, one of the most successful OTC remedies for the common cold on the market. Hensley also invented and developed the underlying nasal delivery system used in the Zicam products. As a means to fast track Zicam to the marketplace, Hensley and his partners co-founded Gel Tech, LLC. (now Zicam, LLC.), with Gum Tech International (now Matrixx Initiatives, Inc.)..

Upon his return to California in 2005, PRB Pharmaceuticals acquired NeoDiagnostics, Inc. and Hensley refined the technology that emerged from his "Taiwan and Hong Kong days" which ultimately led to the development of a suite of broad spectrum anti-viral products. In 2006, Hensley licensed the anti-viral products to Pacific BioPharmaceuticals, which as part of the licensing deal, merged with Abattis Biologix Corporation making Hensley a major shareholder.

In 2007, Hensley founded Nasal Therapeutics, Inc. to develop and market nasal spray technologies and products. That same year, Nasal Therapeutics, Inc. entered into a licensing agreement with Therabiogen, Inc., which allowed them the exclusive right to manufacture, market and sell two nasal therapeutic nasal sprays, Theramax Cold and Flu Relief and Theramax Allergy Relief. As a result of the deal, Hensley became Therabiogen's largest shareholder.

In 2011, after a six-year investigation into PRB Pharmaceuticals' CHINA/US relationships, The company was charged with federal violations. Subsequently, all charges save one misdemeanor were dropped.

Subsequently, Hensley developed a new platform technology based on his theory of altered functioning of EAA transport proteins in neurodegenerative diseases. From this platform, Hensley developed a series of therapies including one for the treatment for migraine headaches. Hensley subsequently formed Migranade, Inc. to further develop the migraine treatment for the market. Hensley and his company received the National Drug Code (NDC) from the FDA which cleared the therapeutic for sale in the United States.

Cosmetics

In the early 2000s, Hensley partnered with a Hong Kong group to form the Hong Kong–based cosmetic company Jovell, Inc. The company currently has over thirty products on the market, and has retail boutique shops and cosmetic counters in major department stores throughout Hong Kong and other parts of Asia.

Entertainment

2008 saw a new corporate direction for Hensley. Seeing the leveling of the playing field across various areas of the entertainment industry and the enormous potential for cross monetization with his other corporate entities, he formed a new holding company and entered the arenas of music, television and film production.

lHensley Records was formed in 2009. In the first year of existence, the record label signed ten recording artists representing goth, alternative, pop and R&B genres.

In 2016, Hensley and his partners acquired the federally registered trademark and set out to expand the brand into a global entertainment empire. Hensley's Corporation is the parent company.